Jan 29 (Reuters) - Insulin delivery device maker Beta Bionics said on Wednesday it raised $204 million in its initial public offering $(IPO.UK)$ at a valuation of about $700 million.
The U.S.-based company said it priced its IPO at $17 per share, the upper-end of its forecasted range of $16 to $17 per share.
The size of the offering was raised to 12 million shares from 10 million shares, the company said.
Beta bucks the recent trend where major IPO candidates such as LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O had to lower their valuation targets.
Beta's shares will start trading on the Nasdaq under the symbol "BBNX" on Thursday.
BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street are the underwriters for the offering.
(Reporting by Kritika Singh in Bengaluru; Editing by Savio D'Souza)
((Kritika.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。